By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


InDex Pharmaceuticals AB 

Scheeles väg 2

Stockholm    SE-171 77  Sweden
Phone: 46-8-50884730 Fax: 46-8-50884739


Key Statistics

Ownership: Private

Web Site: InDex Pharmaceuticals AB


Company News
InDex Pharmaceuticals AB Year End Report 2016 2/27/2017 8:21:27 AM
InDex Pharmaceuticals AB Enters Agreement With CRO For The CONDUCT Study 2/1/2017 7:46:13 AM
InDex Pharmaceuticals AB Gets New Patent Granted In The U.S. 11/3/2016 10:58:39 AM
InDex Pharmaceuticals AB: Results From InDex Pharmaceuticals' COLLECT Study Well Received At UEGW 10/18/2016 2:04:44 PM
InDex Pharmaceuticals AB Publishes Results From COLLECT Study 7/13/2016 8:38:57 AM
InDex Pharmaceuticals AB Receives Grant From Sweden's Innovation Agency Vinnova For Pre-Clinical Development Of DIMS Compounds In Inflammation 5/23/2016 12:45:12 PM
InDex Pharmaceuticals AB Receives FDA Clearance Of IND For Cobitolimod (Kappaproct) Phase IIb Trial 3/7/2016 10:08:22 AM
InDex Pharmaceuticals AB Receives Approval Of The International Nonproprietary Name (INN) Cobitolimod For Their Lead Drug Candidate Kappaproct 2/10/2016 9:19:43 AM
InDex Pharmaceuticals AB Appoints Uli Hacksell And Jesper Wiklund To Its Board Of Directors 7/9/2015 8:36:05 AM
InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis 6/30/2015 9:39:19 AM